VICARIOUS SURGICAL INC

Company Overview

Vicarious Surgical is a pre‑commercial medical‑device company developing a next‑generation single‑port surgical robot that combines miniaturized robotics, dense sensing and stereoscopic 3D visualization to address soft‑tissue abdominal and gynecological procedures (an estimated ~45M addressable procedures annually). The business model targets hospitals and ambulatory surgical centers with a lower‑cost, portable alternative to incumbent multi‑arm systems, selling capital systems and recurring disposable instruments while planning AI/VR enhancements and expanded indications post‑authorization. The company is not yet FDA‑authorized, is advancing a De Novo pathway supported by a prospective IDE pivotal trial, and operates R&D out of Waltham, MA (123 employees as of Jan 2025) with R&D spend of $40.2M in 2024. Vicarious remains pre‑revenue, reported narrowing net losses in 2024/2025 but had ~$24M cash at June 30, 2025 and management expects runway into Q1 2026 absent additional financing, making timely regulatory and capital milestones critical.

Executive Compensation Practices

Given the pre‑revenue, capital‑intensive nature of the business and constrained cash runway, executive pay is likely skewed toward equity‑based and milestone‑linked incentives (stock options, RSUs, and performance awards tied to regulatory, IDE/De Novo, clinical or commercial milestones) rather than large cash bonuses. Compensation committees in Medical Devices commonly emphasize long‑term incentives that align management with successful FDA authorization, reimbursement coverage, strategic partnerships and commercial adoption metrics; cost management and cash‑preservation targets (headcount and OPEX reductions) are also likely to be performance levers here. The company’s use of warrants and significant stock‑based awards means non‑cash compensation (and related valuation remeasurements) can materially affect reported results and dilution expectations, so pay packages may include anti‑dilution or retention structures to retain key engineers and regulatory staff. Expect periodic retention grants around pivotal trial milestones and at fundraising events to minimize turnover given the specialized engineering and clinical skill set required.

Insider Trading Considerations

Insider trading activity for a pre‑commercial device maker like Vicarious will typically cluster around discrete, high‑impact events — FDA interactions (IDE/De Novo filings, STeP enrollment news), pivotal clinical data, partnership or OEM agreements, and financing announcements — all of which can produce sharp share‑price moves and warrant remeasurement swings. Because cash compensation is likely limited and equity grants are a principal element of pay, insiders may exercise options or sell shares to cover tax liabilities or diversify, especially following vesting or financing events; such transactions will appear on Form 4s and can be meaningful signals for traders. Regulatory constraints (Section 16 reporting, blackout windows around material nonpublic information, exchange listing rules and the company’s recent NYSE cure process) plus common use of 10b5‑1 trading plans mean timing and method of insider sales can be structured; watch for scheduled plan filings, large derivative exercises, and disclosed sales concurrent with fundraising which may indicate liquidity needs rather than information‑based trading.